医学
痤疮
炔雌醇
屈螺酮
安慰剂
养生
内科学
随机对照试验
临床终点
胃肠病学
人口
妇科
皮肤病科
病理
替代医学
环境卫生
研究方法
作者
Maloney Jm,Paul Dietze,Daniella Watson,Minoo Niknian,Sooji Lee-Rugh,Carole Sampson-Landers,P. Korner
出处
期刊:PubMed
日期:2009-09-01
卷期号:8 (9): 837-44
被引量:5
摘要
To assess the efficacy of a combined oral contraceptive (COC) containing 3 mg drospirenone (drsp) plus 20 microg ethinylestradiol (EE) administered in 24 days of active treatment followed by a four-day hormone-free interval (24/4 regimen) compared with placebo for the treatment of moderate acne vulgaris.Healthy females (14-45 years old) with moderate facial acne were randomized to 3 mg drsp/20 microg EE 24/4 (n = 270) or placebo (n = 268) for six cycles. The secondary efficacy variables measured included change from baseline to endpoint (cycle 6) in individual lesion count for nodules, papules, pustules, open and closed comedones.There were significantly greater reductions in individual lesion counts from baseline to endpoint in the 3 mg drsp/20 microg EE group than in the placebo group (P < 0.05 from parametric model).The 3 mg drsp/20 microg EE COC administered in a 24/4 regimen significantly reduced acne lesions.
科研通智能强力驱动
Strongly Powered by AbleSci AI